Warren Buffett's Berkshire Hathaway just took a $1.6 billion position in this stock

Berkshire Hathaway disclosed a new, substantial $1.57 billion investment in UnitedHealth Group (UNH) during Q2 2025, acquiring over 5 million shares at an average price of $311.97. This significant healthcare entry, part of a broader portfolio reshuffle, triggered a 12.52% pre-market surge in UNH, signaling renewed market optimism despite the stock currently trading below Berkshire's purchase price. The investment is further notable as other prominent investors, including Michael Burry and David Tepper, also initiated UNH positions in Q2, underscoring a high-conviction play in the sector.

Analysis

Berkshire Hathaway's Q2 2025 13F filing reveals a significant strategic entry into the healthcare sector through a new $1.57 billion position in UnitedHealth Group (UNH). The acquisition of 5,039,564 shares at an average cost of $311.97 per share immediately catalyzed investor sentiment, triggering a 12.52% pre-market surge in UNH stock to $305.48. Despite this strong positive reaction, the stock remains below Berkshire's entry point, suggesting a potential value-oriented thesis. The move's significance is amplified by the concurrent Q2 purchases of UNH by other notable investors, including Michael Burry and David Tepper, indicating a high-conviction consensus among prominent capital allocators. This new investment was part of a broader portfolio adjustment that also saw new stakes in homebuilders D.R. Horton and Lennar, and steel producer Nucor, while trimming positions in technology and finance giants Apple and Bank of America.

Key Decisions for Investors

• The convergence of high-profile investors like Berkshire Hathaway, Michael Burry, and David Tepper into UnitedHealth signals strong institutional conviction, warranting a re-evaluation of the company's long-term value proposition.
• Given that UnitedHealth's price surged to $305.48 but remains below Berkshire's $311.97 average purchase price, investors may consider the current level an attractive entry point to align with a major institutional catalyst.
• Investors should monitor trading volumes and price action around the $311.97 level, as sustained momentum above this cost basis would confirm broader market conviction, whereas a failure to hold could signal that the initial catalyst has been fully priced in.